Genomic landscape and clinical characteristics of patients (pts) with neuroendocrine prostate cancer (NEPC) with or without aggressive variant prostate cancer characterized by molecular signature (AVPC-MS).Hedyeh Ebrahimi, Alex Chehrazi‐Raffle, Koral Shah et al.|Journal of Clinical Oncology|2025Cited by 1
Assessment of time-to-treatment-failure (TTF) as a surrogate endpoint for overall survival (OS) to immune checkpoint inhibitor (ICI) regimens in metastatic renal cell carcinoma (mRCC): Findings from an IMDC analysis.Zachary A. Yochum, Toni K. Choueiri, Renée Maria Saliby et al.|Journal of Clinical Oncology|2025Cited by 0